Neogen Stock Performance
| NEOG Stock | USD 10.05 0.03 0.30% |
The company secures a Beta (Market Risk) of 0.48, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Neogen's returns are expected to increase less than the market. However, during the bear market, the loss of holding Neogen is expected to be smaller as well. At this point, Neogen has a negative expected return of -0.49%. Please make sure to verify Neogen's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Neogen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Neogen has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain nearly stable which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders. ...more
Actual Historical Performance (%)
One Day Return (0.30) | Five Day Return (0.59) | Year To Date Return (15.83) | Ten Year Return (46.31) | All Time Return 2.2 K |
Last Split Factor 2:1 | Last Split Date 2021-06-07 |
1 | Neogen Launches Petrifilm Bacillus cereus Count Plate to Enhance Food Safety Testing Efficiency | 12/17/2024 |
2 | Neogen Q2 Earnings Match Estimates | 01/10/2025 |
3 | Disposition of 2630 shares by Amy Rocklin of Neogen at 15.07 subject to Rule 16b-3 | 01/17/2025 |
4 | Acquisition by Boehm William T of 236 shares of Neogen at 14.89 subject to Rule 16b-3 | 01/22/2025 |
5 | Veterinary Diagnostic Services Market Trends and Revenue Forecasts 2025-2030 Clinical Chemistry, Microbiology, Parasitology, Histopathology, Hematology, Immunol... | 01/29/2025 |
6 | Neogen Posts Better-Than-Expected Sales In Q4 | 01/31/2025 |
7 | Q3 2025 Neogen Chemicals Ltd Earnings Call Transcript | 02/04/2025 |
8 | Neogen Chemicals Limited Just Missed Earnings - But Analysts Have Updated Their Models | 02/06/2025 |
9 | Veterinary Vaccines Market Outlook Report 2025-2029 Veterinary Vaccines Market Set to Grow at a 6.1 percent CAGR Key Trends and Insights into Livestock, Compani... | 02/10/2025 |
10 | Neogen Buy, Sell, or Hold Post Q4 Earnings | 02/11/2025 |
11 | Banque Pictet Cie SA Sells 161,550 Shares of Neogen Co. | 02/14/2025 |
12 | Neogen Corp Stock Price Down 0.67 percent on Feb 19 | 02/19/2025 |
13 | Q4 Earnings Roundup Baxter And The Rest Of The Medical Devices Supplies - Diversified Segment | 02/25/2025 |
14 | Medical Devices Supplies - Diversified Stocks Q4 Teardown Stryker Vs The Rest | 02/28/2025 |
| Begin Period Cash Flow | 163.2 M |
Neogen |
Neogen Relative Risk vs. Return Landscape
If you would invest 1,377 in Neogen on December 1, 2024 and sell it today you would lose (372.00) from holding Neogen or give up 27.02% of portfolio value over 90 days. Neogen is currently does not generate positive expected returns and assumes 2.5697% risk (volatility on return distribution) over the 90 days horizon. In different words, 22% of stocks are less volatile than Neogen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Neogen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Neogen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Neogen, and traders can use it to determine the average amount a Neogen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.191
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | NEOG |
Estimated Market Risk
| 2.57 actual daily | 22 78% of assets are more volatile |
Expected Return
| -0.49 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Neogen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Neogen by adding Neogen to a well-diversified portfolio.
Neogen Fundamentals Growth
Neogen Stock prices reflect investors' perceptions of the future prospects and financial health of Neogen, and Neogen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Neogen Stock performance.
| Return On Equity | -0.16 | ||||
| Return On Asset | 0.0068 | ||||
| Profit Margin | (0.52) % | ||||
| Operating Margin | 0.02 % | ||||
| Current Valuation | 2.93 B | ||||
| Shares Outstanding | 216.94 M | ||||
| Price To Earning | 13.36 X | ||||
| Price To Book | 0.82 X | ||||
| Price To Sales | 2.39 X | ||||
| Revenue | 924.22 M | ||||
| Gross Profit | 448.62 M | ||||
| EBITDA | 182.6 M | ||||
| Net Income | (9.42 M) | ||||
| Cash And Equivalents | 347.71 M | ||||
| Cash Per Share | 3.22 X | ||||
| Total Debt | 906.24 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 9.07 X | ||||
| Book Value Per Share | 12.30 X | ||||
| Cash Flow From Operations | 35.26 M | ||||
| Earnings Per Share | (2.19) X | ||||
| Market Capitalization | 2.18 B | ||||
| Total Asset | 4.55 B | ||||
| Retained Earnings | 555.62 M | ||||
| Working Capital | 434.91 M | ||||
| Current Asset | 250 M | ||||
| Current Liabilities | 28.6 M | ||||
About Neogen Performance
By analyzing Neogen's fundamental ratios, stakeholders can gain valuable insights into Neogen's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Neogen has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Neogen has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 172.59 | 201.93 | |
| Return On Tangible Assets | (0.01) | (0.01) | |
| Return On Capital Employed | 0.01 | 0.01 |
Things to note about Neogen performance evaluation
Checking the ongoing alerts about Neogen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Neogen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Neogen generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 924.22 M. Net Loss for the year was (9.42 M) with profit before overhead, payroll, taxes, and interest of 448.62 M. | |
| Neogen has a poor financial position based on the latest SEC disclosures | |
| Over 100.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Medical Devices Supplies - Diversified Stocks Q4 Teardown Stryker Vs The Rest |
- Analyzing Neogen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Neogen's stock is overvalued or undervalued compared to its peers.
- Examining Neogen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Neogen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Neogen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Neogen's stock. These opinions can provide insight into Neogen's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Neogen Stock analysis
When running Neogen's price analysis, check to measure Neogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neogen is operating at the current time. Most of Neogen's value examination focuses on studying past and present price action to predict the probability of Neogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neogen's price. Additionally, you may evaluate how the addition of Neogen to your portfolios can decrease your overall portfolio volatility.
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation |